Tramadol, Alprazolam Racket: ED Arrests Pharma Dealer for Diverting Psychotropic Drugs, Laundering Rs 3.75 Cr

New Delhi: In a major crackdown on drug-linked money laundering, the Enforcement Directorate (ED) has arrested a pharmaceutical businessman accused of siphoning off nearly 75% of his psychotropic drug stock to the black market and generating Rs 3.75 crore in illicit proceeds.

According to a recent media report in the Hindustan times, officials confirmed that the seized evidence exposes a coordinated interstate supply chain involving controlled medicines such as tramadol and alprazolam, diverted far outside legal channels. The accused, Abhishek Kumar, was produced before the special PMLA court in Mohali, where he was remanded to six days of ED custody. Investigators allege that Kumar played a key role in procuring psychotropic drugs and funneling them into illegal distribution networks through his firm.

The ED initiated the money-laundering investigation based on an FIR registered by Punjab Police under relevant sections of the Narcotic Drugs and Psychotropic Substances (NDPS) Act concerning interstate trafficking of psychotropic tablets and capsules, all of which are tightly regulated under Indian law.

In June this year, ED teams carried out searches at 16 premises linked to Abhishek Kumar and his associates. The searches yielded significant documentary and digital evidence pointing to large-scale diversion of controlled substances, unrecorded transactions and undisclosed stock movement.

The probe revealed that various middlemen, retail distributors and wholesalers were sourcing psychotropic medicines from multiple pharmaceutical manufacturers — including Biogenetic Drugs Pvt Ltd, CB Healthcare, Smilax Pharmachem Drug Industries, Aster Pharma and Soul Health Care (I) Pvt Ltd — before diverting them into the illegal trade. These drugs were sold at inflated prices to peddlers, generating substantial profits outside legitimate supply chains.

According to the ED, Abhishek Kumar obtained these medicines in bulk through his firm, Shree Shyam Medical Agency, and then diverted about 75% of the stock to the black market. At this stage of the probe, officials told Hindustan Times that Kumar allegedly inflated legal invoice box counts to disguise differences between actual and recorded stock, enabling him to siphon off drugs illegally and accumulate ₹3.75 crore in proceeds of crime.

The ED stated the investigation is ongoing and forms part of its broader efforts to dismantle drug-trafficking and money-laundering networks operating across state borders.

Related Posts

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

New Delhi: AstraZeneca’s India-arm has partnered with National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, to build clinical research capabilities at 25 emerging geographies in a bid to extend…

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into papillary-only non-muscle-invasive bladder cancer (NMIBC). Wednesday’s approval comes nearly three months ahead…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction